News coverage about Intellia Therapeutics (NASDAQ:NTLA) has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intellia Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.3683027073372 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Intellia Therapeutics Inc (NTLA) Expected to Post Quarterly Sales of $9.17 Million (americanbankingnews.com)
- Zacks: Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.43 EPS (americanbankingnews.com)
- Intellia Therapeutics Inc. (NASDAQ:NTLA) – An Eye on Price to Earnings Ratio – Nasdaq Journal (press release) (nasdaqjournal.com)
- Investor’s Alert (Volatility Analysis) – Intellia Therapeutics Inc., (NASDAQ: NTLA) – Stock Watch (stocksnewstimes.com)
- Investors Alert on Intellia Therapeutics Inc. (NTLA) – Wall Street Morning (wallstreetmorning.com)
Shares of Intellia Therapeutics (NASDAQ NTLA) opened at $19.37 on Thursday. Intellia Therapeutics has a 12 month low of $10.83 and a 12 month high of $33.34. The company has a market capitalization of $678.77, a price-to-earnings ratio of -12.42 and a beta of 1.60.
A number of research analysts have issued reports on the company. Oppenheimer reiterated a “hold” rating on shares of Intellia Therapeutics in a research report on Monday, December 18th. TheStreet lowered Intellia Therapeutics from a “c-” rating to a “d” rating in a research report on Thursday, December 14th. BidaskClub lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 15th. ValuEngine downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, Barclays reissued a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $30.17.
In other news, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Nessan Bermingham sold 111,500 shares of the business’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $20.34, for a total value of $2,267,910.00. Following the sale, the chief executive officer now directly owns 696,000 shares in the company, valued at $14,156,640. The disclosure for this sale can be found here. Insiders sold a total of 1,971,283 shares of company stock worth $37,137,161 in the last three months. Company insiders own 12.80% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
What are top analysts saying about Intellia Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellia Therapeutics and related companies.